GlaxoSmithKline admits problems with its drugs

GlaxoSmithKline pills
GlaxoSmithKline pills

After years of American drugmakers touting the benefits of U.S. drugs and warning about buying cheaper drugs from somewhere else, a major U.S. drugmaker is admitting that some of its drugs may not have been so good after all.

In what was a revealing and embarrassing admission, GlaxoSmithKline agreed yesterday to pay $750 million to resolve criminal and civil charges that it improperly produced the anti-depressant drug Paxil CR, the topical antibiotic Bactroban, anti-nausea medicine Kytril and diabetes drug Avandamet at a since-closed Puerto Rico plant.